Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 456

1.

Safety, Tolerability, Pharmacokinetics, and Drug Interaction Potential of SPR741, An Intravenous Potentiator, After Single and Multiple Ascending Doses and When Combined with Beta-Lactam Antibiotics in Healthy Subjects.

Eckburg PB, Lister T, Walpole S, Keutzer T, Utley L, Tomayko J, Kopp E, Farinola N, Coleman S.

Antimicrob Agents Chemother. 2019 Jul 1. pii: AAC.00892-19. doi: 10.1128/AAC.00892-19. [Epub ahead of print]

2.

Assessment of the In Vivo Activity of SPR741 in Combination with Azithromycin against Multidrug-Resistant Enterobacteriaceae Isolates in the Neutropenic Murine Thigh Infection Model.

Stainton SM, Abdelraouf K, Utley L, Pucci MJ, Lister T, Nicolau DP.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e00239-18. doi: 10.1128/AAC.00239-18. Print 2018 Jul.

3.

Economic evaluation of an electrochemical process for the recovery of metals from electronic waste.

Diaz LA, Lister TE.

Waste Manag. 2018 Apr;74:384-392. doi: 10.1016/j.wasman.2017.11.050. Epub 2017 Dec 8.

PMID:
29229181
4.

SPR741, an Antibiotic Adjuvant, Potentiates the In Vitro and In Vivo Activity of Rifampin against Clinically Relevant Extensively Drug-Resistant Acinetobacter baumannii.

Zurawski DV, Reinhart AA, Alamneh YA, Pucci MJ, Si Y, Abu-Taleb R, Shearer JP, Demons ST, Tyner SD, Lister T.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01239-17. doi: 10.1128/AAC.01239-17. Print 2017 Dec.

5.

The 67P/Churyumov-Gerasimenko observation campaign in support of the Rosetta mission.

Snodgrass C, A'Hearn MF, Aceituno F, Afanasiev V, Bagnulo S, Bauer J, Bergond G, Besse S, Biver N, Bodewits D, Boehnhardt H, Bonev BP, Borisov G, Carry B, Casanova V, Cochran A, Conn BC, Davidsson B, Davies JK, de León J, de Mooij E, de Val-Borro M, Delacruz M, DiSanti MA, Drew JE, Duffard R, Edberg NJT, Faggi S, Feaga L, Fitzsimmons A, Fujiwara H, Gibb EL, Gillon M, Green SF, Guijarro A, Guilbert-Lepoutre A, Gutiérrez PJ, Hadamcik E, Hainaut O, Haque S, Hedrosa R, Hines D, Hopp U, Hoyo F, Hutsemékers D, Hyland M, Ivanova O, Jehin E, Jones GH, Keane JV, Kelley MSP, Kiselev N, Kleyna J, Kluge M, Knight MM, Kokotanekova R, Koschny D, Kramer EA, López-Moreno JJ, Lacerda P, Lara LM, Lasue J, Lehto HJ, Levasseur-Regourd AC, Licandro J, Lin ZY, Lister T, Lowry SC, Mainzer A, Manfroid J, Marchant J, McKay AJ, McNeill A, Meech KJ, Micheli M, Mohammed I, Monguió M, Moreno F, Muñoz O, Mumma MJ, Nikolov P, Opitom C, Ortiz JL, Paganini L, Pajuelo M, Pozuelos FJ, Protopapa S, Pursimo T, Rajkumar B, Ramanjooloo Y, Ramos E, Ries C, Riffeser A, Rosenbush V, Rousselot P, Ryan EL, Santos-Sanz P, Schleicher DG, Schmidt M, Schulz R, Sen AK, Somero A, Sota A, Stinson A, Sunshine JM, Thompson A, Tozzi GP, Tubiana C, Villanueva GL, Wang X, Wooden DH, Yagi M, Yang B, Zaprudin B, Zegmott TJ.

Philos Trans A Math Phys Eng Sci. 2017 Jul 13;375(2097). pii: 20160249. doi: 10.1098/rsta.2016.0249.

6.

Potentiation of Antibiotic Activity by a Novel Cationic Peptide: Potency and Spectrum of Activity of SPR741.

Corbett D, Wise A, Langley T, Skinner K, Trimby E, Birchall S, Dorali A, Sandiford S, Williams J, Warn P, Vaara M, Lister T.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00200-17. doi: 10.1128/AAC.00200-17. Print 2017 Aug.

7.

Use of illuminance as a guide to effective light delivery during daylight photodynamic therapy in the U.K.

O'Mahoney P, Khazova M, Higlett M, Lister T, Ibbotson S, Eadie E.

Br J Dermatol. 2017 Jun;176(6):1607-1616. doi: 10.1111/bjd.15146. Epub 2017 Apr 5. Erratum in: Br J Dermatol. 2018 Aug;179(2):546.

PMID:
27775832
8.

Treatment of Gram-negative bacterial infections by potentiation of antibiotics.

Zabawa TP, Pucci MJ, Parr TR Jr, Lister T.

Curr Opin Microbiol. 2016 Oct;33:7-12. doi: 10.1016/j.mib.2016.05.005. Epub 2016 May 25. Review.

PMID:
27232956
9.

Design and structure-activity relationships of novel inhibitors of human rhinovirus 3C protease.

Kawatkar SP, Gagnon M, Hoesch V, Tiong-Yip C, Johnson K, Ek M, Nilsson E, Lister T, Olsson L, Patel J, Yu Q.

Bioorg Med Chem Lett. 2016 Jul 15;26(14):3248-3252. doi: 10.1016/j.bmcl.2016.05.066. Epub 2016 May 24.

PMID:
27265257
10.

Corrigendum: Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma.

Okosun J, Wolfson RL, Wang J, Araf S, Wilkins L, Castellano BM, Escudero-Ibarz L, Seraihi AF, Richter J, Bernhart SH, Efeyan A, Iqbal S, Matthews J, Clear A, Guerra-Assunção JA, Bödör C, Quentmeier H, Mansbridge C, Johnson P, Davies A, Strefford JC, Packham G, Barrans S, Jack A, Du MQ, Calaminici M, Lister TA, Auer R, Montoto S, Gribben JG, Siebert R, Chelala C, Zoncu R, Sabatini DM, Fitzgibbon J.

Nat Genet. 2016 May 27;48(6):700. doi: 10.1038/ng0616-700b. No abstract available.

PMID:
27230687
11.

Indoor radon measurements in south west England explained by topsoil and stream sediment geochemistry, airborne gamma-ray spectroscopy and geology.

Ferreira A, Daraktchieva Z, Beamish D, Kirkwood C, Lister TR, Cave M, Wragg J, Lee K.

J Environ Radioact. 2018 Jan;181:152-171. doi: 10.1016/j.jenvrad.2016.05.007. Epub 2016 May 20.

PMID:
27216317
12.

Comparative assessment of methods for estimating tree canopy cover across a rural-to-urban gradient in the mid-Atlantic region of the USA.

Riemann R, Liknes G, O'Neil-Dunne J, Toney C, Lister T.

Environ Monit Assess. 2016 May;188(5):297. doi: 10.1007/s10661-016-5281-8. Epub 2016 Apr 18.

PMID:
27090528
13.

Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma.

Okosun J, Wolfson RL, Wang J, Araf S, Wilkins L, Castellano BM, Escudero-Ibarz L, Al Seraihi AF, Richter J, Bernhart SH, Efeyan A, Iqbal S, Matthews J, Clear A, Guerra-Assunção JA, Bödör C, Quentmeier H, Mansbridge C, Johnson P, Davies A, Strefford JC, Packham G, Barrans S, Jack A, Du MQ, Calaminici M, Lister TA, Auer R, Montoto S, Gribben JG, Siebert R, Chelala C, Zoncu R, Sabatini DM, Fitzgibbon J.

Nat Genet. 2016 Feb;48(2):183-8. doi: 10.1038/ng.3473. Epub 2015 Dec 21. Erratum in: Nat Genet. 2016 May 27;48(6):700.

14.

Life expectancy of young adults with follicular lymphoma.

Conconi A, Lobetti-Bodoni C, Montoto S, Lopez-Guillermo A, Coutinho R, Matthews J, Franceschetti S, Bertoni F, Moccia A, Rancoita PM, Gribben J, Cavalli F, Gaidano G, Lister TA, Montserrat E, Ghielmini M, Zucca E.

Ann Oncol. 2015 Nov;26(11):2317-22. doi: 10.1093/annonc/mdv376. Epub 2015 Sep 11.

PMID:
26362567
15.

Reply to B. Bennani-Baiti et al, H.J.A. Adams et al, E. Laffon et al, and E.A. Hawkes et al.

Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Müeller S, Schwartz LH, Zucca E, Fisher RI, Trotman J, Hoekstra OS, Hicks RJ, O'Doherty MJ, Hustinx R, Biggi A, Cavalli F, Lister TA, Cheson BD.

J Clin Oncol. 2015 Apr 1;33(10):1221-3. doi: 10.1200/JCO.2014.59.9373. Epub 2015 Feb 17. No abstract available.

PMID:
25691678
16.

Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.

Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA; Alliance, Australasian Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group; European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisation for Research; Treatment of Cancer/Dutch Hemato-Oncology Group; Grupo Español de Médula Ósea; German High-Grade Lymphoma Study Group; German Hodgkin's Study Group; Japanese Lymphorra Study Group; Lymphoma Study Association; NCIC Clinical Trials Group; Nordic Lymphoma Study Group; Southwest Oncology Group; United Kingdom National Cancer Research Institute.

J Clin Oncol. 2014 Sep 20;32(27):3059-68.

17.

Variations in laser energy outputs over a series of simulated treatments.

Lister TS, Brewin MP.

Br J Dermatol. 2014 Oct;171(4):806-12. doi: 10.1111/bjd.13228. Epub 2014 Sep 30.

PMID:
24975852
18.

Parenthood in long-term survivors after CHOP with or without etoposide treatment for aggressive lymphoma - response to Meissner et al.

Greaves P, Lister TA, Gribben JG.

Br J Haematol. 2014 Aug;166(4):615-6. doi: 10.1111/bjh.12874. Epub 2014 Apr 2. No abstract available.

PMID:
24689447
19.

Potential strategies for increasing drug-discovery productivity.

Cumming JG, Finlay MR, Giordanetto F, Hemmerling M, Lister T, Sanganee H, Waring MJ.

Future Med Chem. 2014 Apr;6(5):515-27. doi: 10.4155/fmc.14.7.

PMID:
24649955
20.

Laser therapy and photosensitive medication: a review of the evidence.

Kerstein RL, Lister T, Cole R.

Lasers Med Sci. 2014 Jul;29(4):1449-52. doi: 10.1007/s10103-014-1553-0. Epub 2014 Mar 4. Review.

PMID:
24590242
21.

Treatment of Hodgkin lymphoma: a 50-year perspective.

Canellos GP, Rosenberg SA, Friedberg JW, Lister TA, Devita VT.

J Clin Oncol. 2014 Jan 20;32(3):163-8. doi: 10.1200/JCO.2013.53.1194. No abstract available.

PMID:
24441526
22.

Prevention or treatment of hypertrophic burn scarring: a review of when and how to treat with the pulsed dye laser.

Brewin MP, Lister TS.

Burns. 2014 Aug;40(5):797-804. doi: 10.1016/j.burns.2013.12.017. Epub 2014 Jan 15. Review.

PMID:
24439925
23.

New natural products as new leads for antibacterial drug discovery.

Brown DG, Lister T, May-Dracka TL.

Bioorg Med Chem Lett. 2014 Jan 15;24(2):413-8. doi: 10.1016/j.bmcl.2013.12.059. Epub 2013 Dec 22. Review.

PMID:
24388805
24.

Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma.

Okosun J, Bödör C, Wang J, Araf S, Yang CY, Pan C, Boller S, Cittaro D, Bozek M, Iqbal S, Matthews J, Wrench D, Marzec J, Tawana K, Popov N, O'Riain C, O'Shea D, Carlotti E, Davies A, Lawrie CH, Matolcsy A, Calaminici M, Norton A, Byers RJ, Mein C, Stupka E, Lister TA, Lenz G, Montoto S, Gribben JG, Fan Y, Grosschedl R, Chelala C, Fitzgibbon J.

Nat Genet. 2014 Feb;46(2):176-181. doi: 10.1038/ng.2856. Epub 2013 Dec 22.

25.

New antibacterial agents: patent applications published in 2011.

Keating TA, Lister T, Verheijen JC.

Pharm Pat Anal. 2014 Jan;3(1):87-112. doi: 10.4155/ppa.13.65. Review.

PMID:
24354981
26.

Fertility and sexual function in long-term survivors of haematological malignancy: using patient-reported outcome measures to assess a neglected area of need in the late effects clinic.

Greaves P, Sarker SJ, Chowdhury K, Johnson R, Matthews J, Matthews R, Smith M, Korszun A, Gribben JG, Lister TA.

Br J Haematol. 2014 Feb;164(4):526-35. doi: 10.1111/bjh.12651. Epub 2013 Nov 15.

PMID:
24236665
27.

Nutrient deficiencies associated with nutrition-focused physical findings of the oral cavity.

Radler DR, Lister T.

Nutr Clin Pract. 2013 Dec;28(6):710-21. doi: 10.1177/0884533613507284. Epub 2013 Oct 25.

PMID:
24163321
28.

Electromagnetic interference from lasers and intense light sources in the treatment of patients with artificial pacemakers and other implantable cardiac devices.

Lister T, Grant L, Lee SM, Cole RP, Jones A, Taylor T, Mayo A, Wright PA.

Lasers Med Sci. 2015 Jul;30(5):1619-22. doi: 10.1007/s10103-013-1470-7. Epub 2013 Oct 27.

PMID:
24162308
29.

A new Monte Carlo program for simulating light transport through Port Wine Stain skin.

Lister T, Wright PA, Chappell PH.

Lasers Med Sci. 2014 May;29(3):1017-28. doi: 10.1007/s10103-013-1443-x. Epub 2013 Oct 19.

PMID:
24142045
30.

EZH2 mutations are frequent and represent an early event in follicular lymphoma.

Bödör C, Grossmann V, Popov N, Okosun J, O'Riain C, Tan K, Marzec J, Araf S, Wang J, Lee AM, Clear A, Montoto S, Matthews J, Iqbal S, Rajnai H, Rosenwald A, Ott G, Campo E, Rimsza LM, Smeland EB, Chan WC, Braziel RM, Staudt LM, Wright G, Lister TA, Elemento O, Hills R, Gribben JG, Chelala C, Matolcsy A, Kohlmann A, Haferlach T, Gascoyne RD, Fitzgibbon J.

Blood. 2013 Oct 31;122(18):3165-8. doi: 10.1182/blood-2013-04-496893. Epub 2013 Sep 19.

31.

Breast cancer risk following Hodgkin lymphoma radiotherapy in relation to menstrual and reproductive factors.

Cooke R, Jones ME, Cunningham D, Falk SJ, Gilson D, Hancock BW, Harris SJ, Horwich A, Hoskin PJ, Illidge T, Linch DC, Lister TA, Lucraft HH, Radford JA, Stevens AM, Syndikus I, Williams MV; England and Wales Hodgkin Lymphoma Follow-up Group, Swerdlow AJ.

Br J Cancer. 2013 Jun 11;108(11):2399-406. doi: 10.1038/bjc.2013.219. Epub 2013 May 7.

32.

Finite element analysis of thermal and acoustic processes during laser tattoo removal.

Humphries A, Lister TS, Wright PA, Hughes MP.

Lasers Surg Med. 2013 Feb;45(2):108-15. doi: 10.1002/lsm.22107. Epub 2012 Dec 31.

PMID:
23280416
33.

Simulating light transport through skin for color prediction of port wine stain lesions: a review.

Lister T, Wright PA, Chappell PH.

J Biomed Opt. 2012 Nov;17(11):110901. doi: 10.1117/1.JBO.17.11.110901. Review.

PMID:
23151537
34.

Myeloablative chemotherapy for chemo-sensitive recurrent follicular lymphoma: potential benefit in second relapse.

Montoto S, Matthews J, Greaves P, Lillington D, Anderson D, Gribben JG, Lister TA.

Haematologica. 2013 Apr;98(4):620-5. doi: 10.3324/haematol.2012.069583. Epub 2012 Nov 9.

35.

Optical properties of human skin.

Lister T, Wright PA, Chappell PH.

J Biomed Opt. 2012 Sep;17(9):90901-1. doi: 10.1117/1.JBO.17.9.090901. Review.

PMID:
23085902
36.

Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome.

Greaves P, Clear A, Coutinho R, Wilson A, Matthews J, Owen A, Shanyinde M, Lister TA, Calaminici M, Gribben JG.

J Clin Oncol. 2013 Jan 10;31(2):256-62. doi: 10.1200/JCO.2011.39.9881. Epub 2012 Oct 8. Erratum in: J Clin Oncol. 2017 Apr 1;35(10):1140.

37.

Determination of the thermal and physical properties of black tattoo ink using compound analysis.

Humphries A, Lister TS, Wright PA, Hughes MP.

Lasers Med Sci. 2013 Jul;28(4):1107-12. doi: 10.1007/s10103-012-1198-9. Epub 2012 Sep 15.

PMID:
22983425
38.

Letter regarding "Enhanced port-wine stain lightening achieved with combined treatment of selective photothermolysis and imiquimod".

Lister T.

Dermatol Surg. 2012 Aug;38(8):1414-5. doi: 10.1111/j.1524-4725.2012.02492.x. No abstract available.

PMID:
22861064
39.

Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin's lymphoma in England and Wales: a National Cohort Study.

Swerdlow AJ, Cooke R, Bates A, Cunningham D, Falk SJ, Gilson D, Hancock BW, Harris SJ, Horwich A, Hoskin PJ, Linch DC, Lister TA, Lucraft HH, Radford JA, Stevens AM, Syndikus I, Williams MV.

J Clin Oncol. 2012 Aug 1;30(22):2745-52. doi: 10.1200/JCO.2011.38.8835. Epub 2012 Jun 25.

PMID:
22734026
40.

T-cell replete fludarabine/cyclophosphamide reduced intensity allogeneic stem cell transplantation for lymphoid malignancies.

Auer RL, MacDougall F, Oakervee HE, Taussig D, Davies JK, Syndercombe-Court D, Agrawal S, Cavenagh JD, Lister TA, Gribben JG.

Br J Haematol. 2012 Jun;157(5):580-5. doi: 10.1111/j.1365-2141.2012.09106.x. Epub 2012 Mar 26.

PMID:
22449197
41.

Overexpression of wild-type or mutants forms of CEBPA alter normal human hematopoiesis.

Quintana-Bustamante O, Lan-Lan Smith S, Griessinger E, Reyal Y, Vargaftig J, Lister TA, Fitzgibbon J, Bonnet D.

Leukemia. 2012 Jul;26(7):1537-46. doi: 10.1038/leu.2012.38. Epub 2012 Feb 10.

42.

Susceptibility of the pilot balloon of the disposable laryngeal mask airway to puncture during laser therapy.

Chilcott A, Lister TS, Geary PM, Wright PA.

Anaesthesia. 2012 May;67(5):487-92. doi: 10.1111/j.1365-2044.2011.07025.x. Epub 2012 Feb 11.

43.

Discovery of LFF571: an investigational agent for Clostridium difficile infection.

LaMarche MJ, Leeds JA, Amaral A, Brewer JT, Bushell SM, Deng G, Dewhurst JM, Ding J, Dzink-Fox J, Gamber G, Jain A, Lee K, Lee L, Lister T, McKenney D, Mullin S, Osborne C, Palestrant D, Patane MA, Rann EM, Sachdeva M, Shao J, Tiamfook S, Trzasko A, Whitehead L, Yifru A, Yu D, Yan W, Zhu Q.

J Med Chem. 2012 Mar 8;55(5):2376-87. doi: 10.1021/jm201685h. Epub 2012 Feb 23.

PMID:
22315981
44.

Early relapse and refractory disease remain risk factors in the anthracycline and autologous transplant era for patients with relapsed/refractory classical Hodgkin lymphoma: a single centre intention-to-treat analysis.

Greaves P, Wilson A, Matthews J, Brown DL, Auer R, Montoto S, Lister TA, Gribben JG.

Br J Haematol. 2012 Apr;157(2):201-4. doi: 10.1111/j.1365-2141.2011.08993.x. Epub 2012 Jan 9.

PMID:
22224653
45.

Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study.

Swerdlow AJ, Higgins CD, Smith P, Cunningham D, Hancock BW, Horwich A, Hoskin PJ, Lister TA, Radford JA, Rohatiner AZ, Linch DC.

J Clin Oncol. 2011 Nov 1;29(31):4096-104. doi: 10.1200/JCO.2011.34.8268. Epub 2011 Oct 3.

PMID:
21969511
46.

Frequency of leukemic initiating cells does not depend on the xenotransplantation model used.

Vargaftig J, Taussig DC, Griessinger E, Anjos-Afonso F, Lister TA, Cavenagh J, Oakervee H, Gribben J, Bonnet D.

Leukemia. 2012 Apr;26(4):858-60. doi: 10.1038/leu.2011.250. Epub 2011 Sep 16. No abstract available.

47.

Heterogeneous sensitivity of human acute myeloid leukemia to β-catenin down-modulation.

Gandillet A, Park S, Lassailly F, Griessinger E, Vargaftig J, Filby A, Lister TA, Bonnet D.

Leukemia. 2011 May;25(5):770-780. doi: 10.1038/leu.2011.17. Epub 2011 Feb 22.

48.

SNP rs6457327 in the HLA region on chromosome 6p is predictive of the transformation of follicular lymphoma.

Wrench D, Leighton P, Skibola CF, Conde L, Cazier JB, Matthews J, Iqbal S, Carlotti E, Bödör C, Montoto S, Calaminici M, Gribben JG, Lister TA, Fitzgibbon J.

Blood. 2011 Mar 17;117(11):3147-50. doi: 10.1182/blood-2010-10-315382. Epub 2011 Jan 13.

49.

Differential susceptibility of astrocytic and neuronal function to 3-chloropropanediol in the rat inferior colliculus.

Brown AM, Skamarauskas J, Lister T, Madjd A, Ray DE.

J Neurochem. 2011 Mar;116(6):996-1004. doi: 10.1111/j.1471-4159.2010.07138.x. Epub 2011 Jan 24.

50.

AML1/ETO proteins control POU4F1/BRN3A expression and function in t(8;21) acute myeloid leukemia.

Dunne J, Gascoyne DM, Lister TA, Brady HJ, Heidenreich O, Young BD.

Cancer Res. 2010 May 15;70(10):3985-95. doi: 10.1158/0008-5472.CAN-09-3604. Epub 2010 May 11.

Supplemental Content

Loading ...
Support Center